Phase II study of vinorelbine in patients with hormone refractory prostate cancer

被引：0
|
作者：
Caty, A [1 ]
Oudard, S [1 ]
Humblet, Y [1 ]
Beauduin, M [1 ]
Suc, E [1 ]
Gil, T [1 ]
Rolland, F [1 ]
Houyau, P [1 ]
Sun, X [1 ]
Montcuquet, P [1 ]
Breza, J [1 ]
Favreau, E [1 ]
Tresca, P [1 ]
Chopin, D [1 ]
机构：
[1] CTR OSCAR LAMBRET,F-59020 LILLE,FRANCE
来源：
EUROPEAN JOURNAL OF CANCER | 1997年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：135 / 135
页数：1
相关论文
共 50 条
  • [21] Gemcitabine in hormone-refractory prostate cancer: A phase II study
    Reissigl, A
    Brenner, H
    Chaitchik, S
    Sola, C
    Stackl, W
    Janko, C
    Krejcy, K
    ANNALS OF ONCOLOGY, 1998, 9 : 64 - 64
  • [22] Phase II study of single agent gemcitabine in patients with hormone refractory prostate cancer (HRPC).
    Nilsson, S
    Holmberg, M
    Ljung, G
    Pettersson-Skjold, D
    Blom, R
    Ullén, A
    Westberg, R
    Nilsson, I
    Lennernas, B
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 432S - 432S
  • [23] Phase II study of vinorelbine in patients with androgen-independent prostate cancer
    Oudard, S
    Caty, A
    Humblet, Y
    Beauduin, M
    Suc, E
    Piccart, M
    Rolland, F
    Fumoleau, P
    Bugat, R
    Houyau, P
    Monnier, A
    Sun, X
    Montcuquet, P
    Breza, J
    Novak, J
    Gil, T
    Chopin, D
    ANNALS OF ONCOLOGY, 2001, 12 (06) : 847 - 852
  • [24] Phase II study of topotecan in metastatic hormone-refractory prostate cancer
    Hudes, GR
    Kosierowski, R
    Greenberg, R
    Ramsey, HE
    Fox, SC
    Ozols, RF
    McAleer, CA
    Giantonio, BJ
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (03) : 235 - 240
  • [25] Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer
    Eklund, John
    Kozloff, Mark
    Vlamakis, Joy
    Starr, Alexander
    Mariott, Margaret
    Gallot, Lilia
    Jovanovic, Borko
    Schilder, Lawrence
    Robin, Erwin
    Pins, Michael
    Bergan, Raymond C.
    CANCER, 2006, 106 (11) : 2459 - 2465
  • [26] A phase II study of paclitaxel and vinorelbine (Pac-Vin) in hormone-refractory metastatic prostate cancer (HRPC): A final update
    Sewak, S.
    Kosmider, S.
    Ganju, V.
    Woollett, A.
    Le, B.
    Yeo, E.
    Henry, M.
    Bell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting
    Sewak, S.
    Kosmider, S.
    Ganju, V.
    Woollett, A.
    Yeow, E. G.
    Le, B.
    Henry, M.
    Debrincat, M. A.
    Bell, R.
    INTERNAL MEDICINE JOURNAL, 2010, 40 (03) : 201 - 208
  • [28] A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group
    Moore, M. M.
    Stockler, M.
    Lim, R.
    Mok, T. S. K.
    Millward, M.
    Boyer, M. J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (05) : 845 - 850
  • [29] A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group
    M. M. Moore
    M. Stockler
    R. Lim
    T. S. K. Mok
    M. Millward
    M. J. Boyer
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 845 - 850
  • [30] Phase II study of ketoconazole combined with weekly doxorubicin in patients with hormone-refractory prostate cancer
    Argirovic, D.
    Argirovic, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (08) : 568 - 568
12345